Acs

Note: The only factor Xa inhibitor currently approved for clinical use is fondaparinux. aDoes not include agents in phase 1.

bBiotinylated idraparinux is currently being evaluated in clinical trials.

Abbreviations: ACS, acute coronary syndrome; AF, atrial fibrillation; DVT, deep vein thrombosis; PE, pulmonary embolism; VTE, venous thromboembolism.

Note: The only factor Xa inhibitor currently approved for clinical use is fondaparinux. aDoes not include agents in phase 1.

bBiotinylated idraparinux is currently being evaluated in clinical trials.

Abbreviations: ACS, acute coronary syndrome; AF, atrial fibrillation; DVT, deep vein thrombosis; PE, pulmonary embolism; VTE, venous thromboembolism.

sc administration allowing for outpatient therapy, and lower cost. There are however, important unresolved issues including the appropriate dosing regimen of fondapar-inux for the severe hypercoagulability state of HIT, as well as whether the 4-5-day delay to reach peak steady-state levels of fondaparinux is adequate for a condition in which maximal thrombin generation occurs at diagnosis. A single-arm phase II evaluation of fondaparinux in the treatment of isolated HIT is currently being planned.

Your Heart and Nutrition

Your Heart and Nutrition

Prevention is better than a cure. Learn how to cherish your heart by taking the necessary means to keep it pumping healthily and steadily through your life.

Get My Free Ebook


Post a comment